愛康醫療(01789.HK)獲得國家藥品監督管理局批准註冊證
格隆匯 1 月 26日丨愛康醫療(01789.HK)發佈公吿,公司於2021年1月25日獲得國家藥品監督管理局(藥監局)批准的全膝關節假體三類醫療器械註冊證。此次獲批的全膝關節假體是我國首個3D列印人工全膝關節系統,該系統包含了3D列印填充塊在內的整套膝關節骨缺損重建方案。該產品可解決各種原因導致的骨缺損,幫助醫生簡單快捷地重建患者膝關節骨性解剖形態。同時,在微觀上通過3D列印的骨小梁結構促進骨組織的生長和附着,從而達到更好的骨整合效果。
作為國內骨科行業的引領者,愛康醫療在研發方面不斷創新,率先填補多箇中國金屬3D列印產品的空白。自公司成立以來,愛康醫療也一直引領着國產人工膝關節的發展,從2004年推出第一款國產膝關節產品以來,不斷在技術取得突破,本次獲批的膝關節假體標誌着國產膝關節3D列印時代即將到來。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.